Reports
Sale
Global Colorectal Cancer Therapeutics Market Size, Share: By Therapy: Targeted Therapy, Immunotherapy, Chemotherapy, Others; By Cancer Type: Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, Others; By Route of Administration: Oral, Parenteral, Others; By End User; Regional Analysis; Supplier Landscape; 2024-2032
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Colorectal Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Colorectal Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Colorectal Cancer Epidemiology (2016-2031)
5.3 Europe Colorectal Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Colorectal Cancer Epidemiology (2016-2031)
5.5 Latin America Colorectal Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Colorectal Cancer Epidemiology (2016-2031)
6 Global Colorectal Cancer Therapeutics Market Overview
6.1 Global Colorectal Cancer Therapeutics Market Historical Value (2017-2023)
6.2 Global Colorectal Cancer Therapeutics Market Forecast Value (2024-2032)
7 Global Colorectal Cancer Therapeutics Market Landscape
7.1 Colorectal Cancer Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Colorectal Cancer Therapeutics: Product Landscape
7.2.1 Analysis by Therapy type
7.2.2 Analysis by Cancer Type
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by End User
8 Colorectal Cancer Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Colorectal Cancer Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Colorectal Cancer Therapeutics Market Segmentation
11.1 Global Colorectal Cancer Therapeutics Market by Therapy
11.1.1 Market Overview
11.1.2 Targeted Therapy
11.1.3 Immunotherapy
11.1.4 Chemotherapy
11.1.5 Others
11.2 Global Colorectal Cancer Therapeutics Market by Cancer Type
11.2.1 Market Overview
11.2.2 Colorectal Adenocarcinoma
11.2.3 Gastrointestinal Carcinoid Tumors
11.2.4 Others
11.3 Global Colorectal Cancer Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.3.4 Others
11.4 Global Colorectal Cancer Therapeutics Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Homecare
11.4.4 Specialty Clinics
11.4.5 Others
11.5 Global Colorectal Cancer Therapeutics Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Colorectal Cancer Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Colorectal Cancer Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Colorectal Cancer Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Colorectal Cancer Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Colorectal Cancer Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Genentech, Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Eli Lilly and Company
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Bayer AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Amgen Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 F. Hoffmann-La Roche Ltd.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Pfizer Inc
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Novartis AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Accord Healthcare
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Alkem Labs Ltd
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Bausch Health Companies Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Hill Dermaceuticals, Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Bristol-Myers Squibb Company
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Fresenius Kabi USA
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Sagent Pharmaceuticals, Inc.
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 Sanofi
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
24 Colorectal Cancer Therapeutics - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
In 2023, the global market for colorectal cancer therapeutics reached a value of USD 15.75 billion.
The market is anticipated to grow at a CAGR of 6.4% during the forecast period of 2024-2032 to reach a value of USD 27.52 billion by 2032.
The major drivers of the colorectal cancer therapeutics market include the robust healthcare infrastructure, increased treatment rates, inflated pharmaceutical prices, launch of new medicinal products. Growing clinical trials, availability and accessibility of effective treatment options, government initiatives, and emergence of more front-line therapies are also aiding the market growth.
The rising incidence of colorectal cancer and increasing geriatric population are the key industry trends propelling the growth of the market.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Based on therapy, the market is divided into targeted therapy, immunotherapy, and chemotherapy, among others.
The market for colorectal cancer therapeutics, based on cancer type, can be segmented into colorectal adenocarcinoma and gastrointestinal carcinoid tumours, among others.
The several distribution channels of the market are hospital pharmacies, retail pharmacies, and online, among others.
Targeted drugs function unlike the chemotherapy (chemo) drugs. They sometimes function when chemo medicines do not, and they generally have different adverse effects. They can be taken in conjunction with chemo or on its own if chemo is no longer effective.
Surgery is the most effective treatment for colorectal cancer. Other therapies, such as radiation therapy and chemotherapy, may be suggested as well.
The major players in the colorectal cancer therapeutics market are Genentech, Inc., Eli Lilly and Company, Bayer AG, Amgen Inc., F. Hoffmann-La Roche Ltd., and Sanofi SA, among others.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER